Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Interest Expenses (2017)

Crinetics Pharmaceuticals has reported Interest Expenses over the past 1 years, most recently at $1000.0 for Q4 2017.

  • For Q4 2017, Interest Expenses changed N/A year-over-year to $1000.0; the TTM value through Sep 2018 reached $1000.0, changed N/A, while the annual FY2017 figure was $8000.0, 27.27% down from the prior year.
  • Interest Expenses for Q4 2017 was $1000.0 at Crinetics Pharmaceuticals, down from $2000.0 in the prior quarter.
  • Over five years, Interest Expenses peaked at $3000.0 in Q2 2017 and troughed at $1000.0 in Q4 2017.